title: Catheterized guinea pigs infected with Ebola Zaire virus allows safer sequential sampling to determine the pharmacokinetic profile of a phosphatidylserine-targeting monoclonal antibody.
abstract: Sequential sampling from animals challenged with highly pathogenic organisms, such as haemorrhagic fever viruses, is required for many pharmaceutical studies. Using the guinea pig model of Ebola virus infection, a catheterized system was used which had the benefits of allowing repeated sampling of the same cohort of animals, and also a reduction in the use of sharps at high biological containment. Levels of a PS-targeting antibody (Bavituximab) were measured in Ebola-infected animals and uninfected controls. Data showed that the pharmacokinetics were similar in both groups, therefore Ebola virus infection did not have an observable effect on the half-life of the antibody.
authors.affiliation: Health Protection Agency, Porton Down, Salisbury, Wiltshire, UK. stuart.dowall@hpa.org.uk
authors.forename: Stuart
authors.initials: S
authors.lastname: Dowall
authors.forename: Irene
authors.initials: I
authors.lastname: Taylor
authors.forename: Paul
authors.initials: P
authors.lastname: Yeates
authors.forename: Leonie
authors.initials: L
authors.lastname: Smith
authors.forename: Antony
authors.initials: A
authors.lastname: Rule
authors.forename: Linda
authors.initials: L
authors.lastname: Easterbrook
authors.forename: Christine
authors.initials: C
authors.lastname: Bruce
authors.forename: Nicola
authors.initials: N
authors.lastname: Cook
authors.forename: Kara
authors.initials: K
authors.lastname: Corbin-Lickfett
authors.forename: Cyril
authors.initials: C
authors.lastname: Empig
authors.forename: Kyle
authors.initials: K
authors.lastname: Schlunegger
authors.forename: Victoria
authors.initials: V
authors.lastname: Graham
authors.forename: Mike
authors.initials: M
authors.lastname: Dennis
authors.forename: Roger
authors.initials: R
authors.lastname: Hewson
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004195:Disease Models, Animal; D029043:Ebolavirus / Q000472:pathogenicity*; D006168:Guinea Pigs; D019142:Hemorrhagic Fever, Ebola / Q000628:therapy*; D007155:Immunologic Factors / Q000008:administration & dosage / Q000493:pharmacokinetics*; D010718:Phosphatidylserines / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D007155:Immunologic Factors; D010718:Phosphatidylserines; C547825:bavituximab